Who We Are
Vision
Healthcare ecosystem is complex - multiple stakeholders, major differences in clinnical practice, payer systems and policies by country, uneven affordability and access to medicines and new technologes and AI rapidly shaping standard practices. It is important to remember that the patient is always at the center!
At ETI, we help life sciences and healthcare teams close the gap between scientific discovery and real-world patient benefit — turning innovation into adoption through data-driven evidence that is credible, decision-grade, and regulator-ready.
What we believe:
- Evidence must be fit-for-purpose
- Data science must be auditable
- Uncertainty is not a weakness
Outcomes we optimise:
- Higher-quality evidence packages with fewer rework cycles
- Stronger cross-functional alignment
- Clearer decision criteria
Expertise
Priya Kulkarni, Ph.D. is a healthcare leader with 20+ years experience spanning pharmaceutical drug development and digital health, with roles at Genentech, Roche Information Solutions, Merck, and Pfizer. Over the years, she held roles of increasing scientific and strategic leadership, closely working with stakeholders from clinical, regulatory, medical affairs, and commercial functions in the US, EU, and globally across all stages of the development lifecycle, from preclinical, process development to clinical trials, launch and post-market evaluation, in multiple therapeutic areas. Throughout her career, she has led evidence strategies for some of the world's most complex programmes - from breakthrough oncology designation to regulatory submissions for drug-device combinations and AI-powered digital health technologies. She holds a Ph.D. and M.A. in Statistics from UC Santa Barbara and an M.Sc. in Applied Statistics and Informatics from IIT Mumbai.
She founded Evidence to Impact (ETI) because she believes that the hardest part of healthcare innovation is not generating evidence — it is knowing which evidence matters, to whom, and how to generate actionable insights to close the gap between data and decision. At Evidence to Impact, success is measured by decisions unlocked, not by studies completed.
Our Approach
Impact in healthcare is measured by whether evidence changes a decision — a regulator approves, a payer covers, a clinician adopts, a patient benefits.
Evidence creates impact when it is scientifically rigorous enough to be trusted, strategically designed to answer the right question for the right audience, and commercially framed to accelerate adoption. These are not sequential steps — they must be built in from the start.
Work closely with pharma, biotech, healthtech and medtech innovators, CROs and academic teams to design and communicate evidence that stands up to scrutiny statistically, operationally, and strategically.